Please login to the form below

Not currently logged in
Email:
Password:

Therapeutic vaccines

This page shows the latest Therapeutic vaccines news and features for those working in and with pharma, biotech and healthcare.

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

FDA approves GSK’s Priorix vaccine for measles, mumps and rubella

Temi Folaranmi, vice president and vaccines therapeutic area head of US Medical Affairs at GSK said: “Outbreaks of measles in recent years demonstrate how quickly diseases can return without widespread immunisation. ... Outlined in a US Centers for

Latest news

More from news
Approximately 0 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    A partial revision to the Swiss Patents Act and its implementing provisions came into force on 1 January 2019, together with an ordinary revision of the Therapeutic Products Act. ... For example, over the last five years, Lundbeck acquired Prexton

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    You have a broad pipeline of candidates, including therapeutic vaccines, such as your vaccine for prostate cancer in phase 1. ... How big a role do you think therapeutic vaccines will play in future cancer treatment?

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... Vaccines. While the first therapeutic cancer vaccines have reached the market, eg Dendreon’s Provenge and

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Exclusive licence. 522. AC Immune/ Janssen. To develop and commercialise therapeutic anti-Tau vaccines [ACI35, P1] for the treatment of Alzheimer's disease. ... 3 year research collaboration and exclusive licence. 509. Neuropore Therapies/UCB. To develop

  • Pharma deals during July 2014 Pharma deals during July 2014

    Baxter forecasts that its revenues from vaccines will be approximately $300m for 2014. ... CureVac is also eligible to receive clinical, regulatory and commercial milestones of up to $202m, as well as royalty payments associated with products sales of

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...